Bristol-Myers Squibb (BMY - Free Report) closed the most recent trading day at $45.77, moving +0.2% from the previous trading session. This move outpaced the S&P 500's daily loss of 0.95%. At the same time, the Dow lost 0.67%, and the tech-heavy Nasdaq lost 1.51%.
Prior to today's trading, shares of the biopharmaceutical company had lost 2.41% over the past month. This has lagged the Medical sector's gain of 3.89% and the S&P 500's gain of 4.32% in that time.
Wall Street will be looking for positivity from BMY as it approaches its next earnings report date. This is expected to be July 25, 2019. In that report, analysts expect BMY to post earnings of $1.05 per share. This would mark year-over-year growth of 3.96%. Meanwhile, our latest consensus estimate is calling for revenue of $5.98 billion, up 4.82% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.21 per share and revenue of $24.11 billion. These totals would mark changes of +5.78% and +6.88%, respectively, from last year.
Any recent changes to analyst estimates for BMY should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.67% higher. BMY currently has a Zacks Rank of #3 (Hold).
Investors should also note BMY's current valuation metrics, including its Forward P/E ratio of 10.86. This represents a discount compared to its industry's average Forward P/E of 14.83.
Investors should also note that BMY has a PEG ratio of 2.12 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.12 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 76, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Bristol-Myers Squibb (BMY - Free Report) closed the most recent trading day at $45.77, moving +0.2% from the previous trading session. This move outpaced the S&P 500's daily loss of 0.95%. At the same time, the Dow lost 0.67%, and the tech-heavy Nasdaq lost 1.51%.
Prior to today's trading, shares of the biopharmaceutical company had lost 2.41% over the past month. This has lagged the Medical sector's gain of 3.89% and the S&P 500's gain of 4.32% in that time.
Wall Street will be looking for positivity from BMY as it approaches its next earnings report date. This is expected to be July 25, 2019. In that report, analysts expect BMY to post earnings of $1.05 per share. This would mark year-over-year growth of 3.96%. Meanwhile, our latest consensus estimate is calling for revenue of $5.98 billion, up 4.82% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.21 per share and revenue of $24.11 billion. These totals would mark changes of +5.78% and +6.88%, respectively, from last year.
Any recent changes to analyst estimates for BMY should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.67% higher. BMY currently has a Zacks Rank of #3 (Hold).
Investors should also note BMY's current valuation metrics, including its Forward P/E ratio of 10.86. This represents a discount compared to its industry's average Forward P/E of 14.83.
Investors should also note that BMY has a PEG ratio of 2.12 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.12 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 76, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BMY - FREE